Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the appointment of Pete Salzmann, M.D., MBA, to its Board of Directors. Dr. Salzmann brings 20 years of industry experience and currently serves as Chief Executive Officer of Immunovant (IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune diseases. Read more >>